Quadratus Lumborum Block, Transversus Abdominis Plane Block, and Erector Spinae Block in Pediatric Abdominal Surgery

NCT07850596 | Completed

• 1 other identifier: 12/2024 ANET 32
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to compare the analgesic efficacy and safety of Quadratus Lumborum (QL), Transversus Abdominis Plane (TAP), and Erector Spinae Plane (ESP) blocks in pediatric abdominal surgery.

Conditions

Transversus Abdominis Plane Block; Pediatric; Abdominal Surgery; Quadratus Lumborum Block; Erector Spinae Plane Block

Outcome Measures

Primary Outcomes (1)

• Degree of pain

  Degree of pain will be assessed using Wong-Baker FACES for the first 24 hours postoperative at 4, 8,12,16 and 24 hours postoperatively. Wong-Baker FACES Pain Scale, which utilizes a series of 6 faces increasing in pain severity may be used to facilitate communication and assist in pain assessment .

  24 hours postoperatively

Secondary Outcomes (8)

• Total fentanyl consumption

  Intraoperatively

• Heart rate

  Till the end of surgery (Up to 2 hours)

• Mean arterial blood pressure

  Till the end of surgery (Up to 2 hours)

• Time of each block

  Intraoperatively

• Sedation score

  24 hours postoperatively

Study Arms (3)

QL Group

EXPERIMENTAL

Patients received quadratus lumborum (QL) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg.

Drug: Quadratus lumborum (QL) block

TAP group

EXPERIMENTAL

Patients received transversus abdominis plane (TAP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg

Drug: Transversus abdominis plane (TAP) block

ES Group

EXPERIMENTAL

Patients received erector spinae plane (ESP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg.

Drug: Erector spinae plane (ESP) block

Interventions

Quadratus lumborum (QL) block DRUG

Patients received quadratus lumborum (QL) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg.

Also known as: Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg

QL Group

Transversus abdominis plane (TAP) block DRUG

Patients received transversus abdominis plane (TAP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg.

Also known as: Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg

TAP group

Erector spinae plane (ESP) block DRUG

Patients received erector spinae plane (ESP) block with bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg.

Also known as: Bupivacaine 0.25% (0.5 ml/kg) + dexmedetomidine 0.5 mcg/kg

ES Group

Eligibility Criteria

• Age: 3 Years - 12 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Children aged from 3 to12 years.
• Both sexes.
• American Society of Anesthesiologists (ASA) Physical Status I-II.
• Scheduled for pediatric abdominal surgery.

You may not qualify if:

• Allergy or contraindication to bupivacaine or dexmedetomidine.
• Coagulopathy.
• Local infection at the site of the block.
• Neurological or psychiatric disorders affecting pain perception.
• Refusal of the regional technique by parents/guardians.

Sponsors & Collaborators

• Menoufia University: lead

Study Sites (1)

Menoufia University

Shibīn al Kawm, Menoufia, 32951, Egypt

Location

MeSH Terms

Interventions

Dental Occlusion; Bupivacaine; Dexmedetomidine; Parapsychology

Intervention Hierarchy (Ancestors)

Dentistry; Dental Physiological Phenomena; Digestive System and Oral Physiological Phenomena; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Behavioral Sciences; Behavioral Disciplines and Activities

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer of Anesthesia, ICU and Pain Management, Faculty of Medicine, Menoufia University, Egypt.

Study Record Dates

• First Submitted: September 23, 2026
• First Posted: September 30, 2026
• Study Start: January 1, 2025
• Primary Completion: June 1, 2026
• Study Completion: June 1, 2026
• Last Updated: September 30, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)